Literature DB >> 1342296

Update on fibrinogen as a cardiovascular risk factor.

W B Kannel1, R B D'Agostino, A J Belanger.   

Abstract

Mounting data support a causal connection between high-normal fibrinogen levels and atherosclerotic cardiovascular disease. There is clearly a thrombogenic component to atherosclerosis and the onset of clinical manifestations. This offers the possibility to better identify high-risk candidates and also to protect them by reducing blood fibrinogen concentration or blocking its action. The relationship of antecedent fibrinogen to the subsequent development of cardiovascular disease is examined, based on 18 years of surveillance of a cohort of 1274 men and women aged 47 to 79 years who participated in the Framingham Study. The association with the development of peripheral arterial disease and cardiac failure is now examined in addition to previously studied relationships to coronary heart disease and stroke. In men and women, there is a significant age-adjusted relationship of fibrinogen level to coronary heart disease and to cardiovascular disease in general. In women, a significant relationship to cardiac failure and peripheral arterial disease, but not to stroke, was also found. These data on women are unique as they are not available elsewhere. Age-adjusted cardiovascular, all-cause, and coronary heart disease mortality were all related to fibrinogen in both sexes. In men, fibrinogen impact was the greatest for stroke and the least for peripheral arterial disease. For women, the impact on coronary heart disease was greatest. The absolute risk for an elevated fibrinogen level was greatest for coronary heart disease in both sexes. Average fibrinogen values are higher in women and in persons with other risk factors, including hypertension, cigarette smoking, diabetes, obesity, and elevated hematocrit. However, there is an independent contribution of fibrinogen to cardiovascular disease in general and coronary disease in particular, on adjustment for coexistent risk factors. Fibrinogen enhances the risk of cardiovascular disease in hypertensives, diabetics, and cigarette smokers. About half the cardiovascular risk of cigarette smoking appears due to the higher fibrinogen values. Now, five prospective studies document the excess incidence of cardiovascular events in persons with elevated fibrinogen levels within the "normal range." Each standard deviation increase in fibrinogen is associated with a 30% increment of coronary heart disease in men and a 40% increase in women. Fibrinogen should be added to the list of major cardiovascular risk factors. Trials of intervention to lower fibrinogen in high-risk coronary candidates are needed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1342296     DOI: 10.1016/1047-2797(92)90095-8

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  11 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 2.  New approaches to the prevention of atherosclerosis.

Authors:  M Naito; T Hayashi; A Iguchi
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

3.  BARI 2D: A Reanalysis Focusing on Cardiovascular Events.

Authors:  Saul M Genuth; Helen Vlachos; Maria Mori Brooks; John P Bantle; Bernard R Chaitman; Jennifer Green; Sheryl F Kelsey; Spencer B King; Robert McBane; Edward Y Sako; David J Schneider; Michael Steffes; Robert L Frye
Journal:  Mayo Clin Proc       Date:  2019-10-04       Impact factor: 7.616

4.  Influence of Contraceptive Pill Use, Premenopause and Postmenopausal State on Hemostatic Parameters in Ethnic Chinese Women.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

5.  Hyperfibrinogenemia and functional outcome from acute ischemic stroke.

Authors:  Gregory J del Zoppo; David E Levy; Warren W Wasiewski; Arthur M Pancioli; Andrew M Demchuk; James Trammel; Bart M Demaerschalk; Markku Kaste; Gregory W Albers; Eric B Ringelstein
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

6.  Fibulin-1 and fibrinogen in human atherosclerotic lesions.

Authors:  W Scott Argraves; Asashi Tanaka; Elizabeth P Smith; Waleed O Twal; Kelley M Argraves; Daping Fan; Christian C Haudenschild
Journal:  Histochem Cell Biol       Date:  2009-08-20       Impact factor: 4.304

Review 7.  Influence of fibrinogen on cardiovascular disease.

Authors:  W B Kannel
Journal:  Drugs       Date:  1997       Impact factor: 9.546

8.  The longitudinal relation of stress during the menopausal transition to fibrinogen concentrations: results from the Study of Women's Health Across the Nation.

Authors:  April M Falconi; Ellen B Gold; Imke Janssen
Journal:  Menopause       Date:  2016-05       Impact factor: 2.953

Review 9.  Coronary Heart Disease in Postmenopausal Women with Type II Diabetes Mellitus and the Impact of Estrogen Replacement Therapy: A Narrative Review.

Authors:  Marouane Boukhris; Salvatore Davide Tomasello; Francesco Marzà; Sonia Bregante; Francesca Romana Pluchinotta; Alfredo Ruggero Galassi
Journal:  Int J Endocrinol       Date:  2014-07-17       Impact factor: 3.257

10.  Defibrinogen Therapy for Acute Ischemic Stroke: 1332 Consecutive Cases.

Authors:  Jing Chen; Dalong Sun; Mingli Liu; Shufan Zhang; Chuancheng Ren
Journal:  Sci Rep       Date:  2018-06-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.